Journal of the Formosan Medical Association
Volume 108, Issue 9 , Pages 730-735, September 2009

Amelioration of Hypophosphatemic Rickets and Osteoporosis With Pamidronate and Growth Hormone in Lowe Syndrome

  • Jia-Woei Hou

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr Jia-Woei Hou, Department of Pediatrics, Cathay General Hospital, 280 Jen-Ai Road, Section 4, Taipei 106, Taiwan

Department of Pediatrics, Chang Gung Memorial Hospital and Cathay General Hospital, Taipei, Taiwan

Received 10 July 2008; received in revised form 28 November 2008; accepted 6 May 2009.

Article Outline

The oculocerebrorenal syndrome of Lowe, an X-linked multisystem disorder, was diagnosed in a male patient who presented with typical abnormalities of the eyes, kidneys and nervous system. Besides congenital cataracts, renal tubular dysfunction and psychomotor retardation, the patient had also suffered from profound failure to thrive, growth hormone deficiency, severe osteoporosis with hypophosphatemic rickets, and progressive renal dysfunction since early childhood, which were attributed to the metabolic derangements following Fanconi syndrome. Direct sequencing of the OCRL1 gene (responsible for the oculocerebrorenal syndrome of Lowe) revealed a de novo c.2282_2283insT in exon 20, which resulted in premature termination of translation (D762X). After monthly intravenous administration of pamidronate since the age of 17.8 years, his urine creatinine clearance and tubular resorption of phosphate increased slightly and bone mineral density was much improved (Z score increased from −7.3 to −3.3) without deterioration of renal function. Simultaneous growth hormone therapy enhanced the positive response. The beneficial osseous and renal effects of the bisphosphonate, along with growth hormone treatment in Lowe syndrome with hypophosphatemia, may be related to reduced renal calcium and phosphate excretion.

Key Words:  growth hormone , hypophosphatemic rickets , Lowe syndrome , OCRL1 gene , oculocerebrorenal syndrome , pamidronate

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Lowe CU , Terrey M , MacLachlan EA . Organic aciduria, decreased renal ammonia production, hydrophthalmos and mental retardation: a clinical entity . Am J Dis Child . 1952;83:164–184
  2. Richards W , Donnell GN , Wilson WA , et al.   The oculocerebro-renal syndrome of Lowe . Am J Dis Child . 1965;109:185–203
  3. Loi M . Lowe syndrome . Orphanet J Rare Dis . 2006;1:16
  4. Charnas LR , Bernardini I , Rader D , et al.   Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function . N Engl J Med . 1991;324:1318–1325
  5. Holtgrewe JL , Kalen V . Orthopedic manifestations of the Lowe (oculocerebrorenal) syndrome . J Pediatr Orthop . 1986;6:165–171
  6. Lowe M . Structure and function of the Lowe syndrome protein OCRL1 . Traffic . 2005;6:711–719
  7. Constantin A , Laroche M , Moulinier L , et al.   Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate . Rev Rhum Engl Ed . 1995;62:493–500
  8. Rodan GA , Fleisch HA . Bisphosphonates: mechanisms of action . J Clin Invest . 1996;97:2692–2696
  9. Hou JW . Rapidly Progressive scoliosis after successful treatment for osteopenia in Costello syndrome . Am J Med Genet A . 2008;146:393–396
  10. Weger W , Kotanko P , Weger M , et al.   Prevalence and characterization of renal tubular acidosis in patients with osteopenia and osteoporosis and in non-porotic controls . Nephrol Dial Transplant . 2000;15:975–980
  11. Roschinger W , Muntau AC , Rudolph G , et al.   Carrier assessment in families with Lowe oculocerebrorenal syndrome: novel mutations in the OCRL1 gene and correlation of direct DNA diagnosis with ocular examination . Mol Genet Metab . 2000;69:213–222
  12. Addis M , Loi M , Lepiani C , et al.   OCRL mutation analysis in Italian patients with Lowe syndrome . Hum Mutat . 2005;23:524–525
  13. Lee S , Glicklich D , Coco M . Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction . Nephrol Dial Transplant . 2004;19:2870–2873
  14. Markowitz GS , Appel GB , Fine PL , et al.   Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate . J Am Soc Nephrol . 2001;12:1164–1172
  15. Smetana S , Michlin A , Rosenman E , et al.   Pamidronate-induced nephrotoxic tubular necrosis—a case report . Clin Nephrol . 2004;61:63–67
  16. Sheffer-Babila S , Chandra M , Speiser PW . Growth hormone improves growth rate and preserves renal function in Dent disease . J Pediatr Endocrinol Metab . 2008;21:279–286
  17. Valk NK , Erdtsieck RJ , Algra D , et al.   Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass . Clin Endocrinol (Oxf) . 1995;43:317–324

PII: S0929-6646(09)60397-1

doi:10.1016/S0929-6646(09)60397-1

Journal of the Formosan Medical Association
Volume 108, Issue 9 , Pages 730-735, September 2009

Article Tools